New Drug ATR-258 Cuts Fat and Builds Muscle in Early Human Trial
Atrogi's oral GRK2-biased β2-adrenergic drug improved muscle power by 13% and shifted body composition in 8 weeks.
Summary
Atrogi has reported encouraging early human data for ATR-258, a first-in-class oral drug designed to simultaneously reduce fat and increase muscle mass. In a small 8-week open-label study of 13 overweight or obese adults, the drug was associated with a 13% improvement in lower-extremity muscle power, a 1.1 kg reduction in fat mass, and a 0.8 kg gain in lean mass. The drug works by modulating the GRK2-biased β2-adrenergic pathway, selectively targeting skeletal muscle. It was well tolerated across three ascending dose levels. These results represent the first human proof-of-mechanism for this drug class and pave the way for a Phase 2 trial targeting muscle-sparing weight loss and sarcopenia in 2027.
Detailed Summary
A Stockholm-based biotech company, Atrogi, has released promising early human data for its investigational drug ATR-258 — a novel oral compound designed to tackle two of the most consequential aspects of aging-related body composition: excess fat and muscle loss. The findings mark a meaningful step forward in the search for non-invasive, pharmacological tools to combat sarcopenia and obesity simultaneously.
In an 8-week, investigator-initiated, open-label, single-arm study involving 13 overweight or obese participants, ATR-258 demonstrated a mean 13% improvement in lower-extremity muscle power from baseline. Participants also lost an average of 1.1 kg of fat mass while gaining 0.8 kg of lean mass — a body composition shift rarely seen with a single oral agent. The drug was well tolerated across three ascending dose levels, with no safety signals reported.
ATR-258 is a first-in-class GRK2-biased β2-adrenergic receptor modulator. Unlike traditional β2 agonists, which broadly activate adrenergic receptors and can cause cardiovascular side effects, ATR-258 is engineered to selectively engage skeletal muscle tissue. This targeted mechanism may allow the anabolic and lipolytic benefits of adrenergic stimulation without the systemic risks previously associated with similar compounds.
The data build on a June 2025 Cell publication and a prior Phase 1 trial involving 69 subjects. Atrogi plans to present the latest findings at the International Conference on Cachexia, Sarcopenia and Muscle Wasting in December 2026, and intends to initiate a Phase 2 trial in 2027 focused on muscle-sparing weight loss and sarcopenia.
Caveats are significant: the study enrolled only 13 participants, lacked a control arm, and was open-label — meaning results could reflect placebo effects or observer bias. Larger, randomized, placebo-controlled trials are essential before drawing firm conclusions. Still, for readers focused on preserving muscle and managing body composition with age, ATR-258 represents a compelling early-stage candidate worth monitoring.
Key Findings
- ATR-258 improved lower-extremity muscle power by ~13% over 8 weeks in overweight adults.
- Participants lost a mean 1.1 kg of fat mass while gaining 0.8 kg of lean mass simultaneously.
- The drug was well tolerated across three ascending dose levels with no reported safety concerns.
- ATR-258 selectively targets skeletal muscle via GRK2-biased β2-adrenergic modulation, potentially avoiding cardiovascular side effects.
- A Phase 2 trial targeting sarcopenia and muscle-sparing weight loss is planned for 2027.
Methodology
This is a news report summarizing results from an 8-week, investigator-initiated, open-label, single-arm Phase 1b study in 13 subjects; no peer-reviewed publication of these specific results was cited. The source, Longevity.Technology, is a credible longevity-focused outlet, but the data are from a company press release and have not yet undergone independent peer review.
Study Limitations
The study enrolled only 13 participants with no control group or blinding, making it impossible to rule out placebo effects or confounding. All data come from a company announcement rather than a peer-reviewed publication, introducing potential reporting bias. Phase 2 randomized controlled trial results are needed before efficacy and safety can be confirmed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: